CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the 2011 UBS Global Specialty Pharmaceuticals Conference, being held May 24-25 2011 at the UBS offices in London. Mr. Christensen will provide a corporate update regarding the Company’s three major business franchises and value drivers - KALBITOR® (ecallantide), the Licensing and Funded Research Program (LFRP) and the internal pipeline, including label expansion efforts with KALBITOR. The Dyax presentation is scheduled for Tuesday, May 24 at 3:30 PM BST (10:30 AM ET).
